"BioHarvest Hits Major Sales Milestone with VINIA Setting new Records" CEO Ilan Sobel discusses hitting $2 Million USD monthly sales mark and updates progress to Q2 forecast. Watch video: https://bit.ly/45jlwWH
BioHarvest Sciences
Biotechnology Research
Vancouver, British Columbia 2,074 followers
Leveraging the power of Botanical Synthesis technology to develop the next generation of science based Therapeutics
About us
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) is a public biotech company that has developed a patented Botanical Synthesis platform technology capable of growing the active and beneficial compounds in fruit & plants, at an industrial scale, without the need to grow the plant itself. BioHarvest has invested 16 years and >$75M to develop our Botanical Synthesis Technology, which produces unique and patentable botanical compositions which contain a “target optimized” combination of the phyto-medicinal compounds (with high solubility and bio-availability) found in the original plant. No other company has developed a commercially viable plant cell culture platform at the industrial scale of BioHarvest. BioHarvest is focused on leveraging this platform technology across the following business units: 1. Plant Cell Culture Development and Manufacturing: BioHarvest is leveraging its Botanical Synthesis technology to allow global pharmaceutical, cosmeceutical, and nutraceutical partners to develop proprietary botanical formulations with unmatched predictability and consistency, manufactured at industrial scale under exclusive partnerships. 2. Direct to Consumer/Direct to Doctor Nutraceuticals Business Anchored in Science: BioHarvest has built its own direct to consumer business of propriety botanical compositions. The first product, VINIA® was launched into the US in 2021 and has exceeded 50,000 users (>$20M USD Revenue). VINIA® contains multiple polyphenols, including Piceid Resveratrol, with an amount in each daily 400mg capsule that is equivalent to 1,000 grapes, resulting in a powerful nutraceutical that has been clinically proven (in a published double-blind placebo-controlled study), to significantly increase dilation of arteries. This increased dilation of arteries improves blood flow and the delivery of oxygen and nutrients to the body, tissue & organs. BioHarvest is the only company that produces red grape sourced Piceid resveratrol at an industrial scale
- Website
-
https://www.bioharvest.com
External link for BioHarvest Sciences
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Vancouver, British Columbia
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
625 Howe St.
Suite 1140
Vancouver, British Columbia V6C2T6, CA
Employees at BioHarvest Sciences
Updates
-
June 6 News Release--> "BioHarvest Sciences Announces Record $2 Million Monthly Sales". · VINIA® Subscription Growth Drives 101% Year-over-Year Increase in May Product Sales Orders; · Cumulative Customer Reviews Surpass 5,000 View Full release: https://bit.ly/3yXX6G1
-
**New CEO Interview** "BioHarvest Sciences Reports Robust Q1 2024 Financial Growth and Strategic Expansion Plans". Steve Darling of Proactive interviews CEO Ilan Sobel following release of Q1 2024 results. Watch: https://lnkd.in/g9BXRcqN
-
May 30 News Release--> BioHarvest Sciences Reports First Quarter 2024 Financial Results: · Q1 2024 Revenue Increased 147% Year-over-Year to US$5.34 Million Exceeding Previous Guidance · Management Expects Q2 2024 Revenue in the Range of US$5.7-6.0 Million and expects to reach EBITDA break-even in the second half of 2024. · Gross margins in the first quarter of 2024 improved to 56%, as compared to 37% in the same period in the prior financial year. · In the U.S., total subscribers increased by 122%, with Marketing and Sales spend increasing by only 39% compared to the same period in the prior financial year. Read the Full News Release: https://bit.ly/4bGvtQs
-
**5000+ Reviews and counting!!** Thank you to our vocal VINIA community for getting us to this milestone! Go to https://lnkd.in/eikckzaG and filter comments by any search term to see feedback from real people on real results.
-
Thank you to everyone who was able to attend our May 2 Shareholder Update, which focused on Full Year 2023 financials, the acquisition of a new corporate campus announced April 16, and a discussion of our proposed path to a US listing. Watch full video with Q+A: https://bit.ly/3JUvJPn
May 2 2024 Shareholder Update- Full Event with Q+A
https://www.youtube.com/
-
Corporate Update Webinar May 2, 2:30 pm EST. Join CEO Ilan Sobel and Chairman Zaki Rakib for a live discussion of recent milestones and of the FY 2023 Financials released April 30. Register: https://bit.ly/4aTejP8
-
"BioHarvest Sciences Reports Strong Financial Performance for 2023, Eyes Nasdaq Listing". CEO Ilan Sobel interviewed by Proactive Investors- watch interview: https://bit.ly/3y0xJDj
BioHarvest Sciences Reports Strong Financial Performance for 2023, Eyes Nasdaq Listing
https://www.youtube.com/
-
News Release--> BioHarvest Sciences Reports Fourth Quarter and Full Year 2023 Financial Results • Full Year 2023 Revenue Increased 2.3x to $12.7 Million USD • The Company expects Q1 2024 Revenue to be $5.2 million to $5.3 million and is providing Q2 2024 Revenue Guidance of $5.7-$6.0 million • Fourth quarter 2023 gross margins improved to 51%, as compared to 27% in the fourth quarter of 2022. Full year 2023 gross margins improved to 45%, as compared to 22% in 2022.
-
"BioHarvest Sciences secures new state of the art 80,0000 square foot manufacturing facility." CEO Ilan Sobel discusses new Corporate Campus and our plans to consolidate all aspects of research and production into one location. Watch Proactive interview: https://lnkd.in/gEXe-4uU
BioHarvest Sciences secures new state of the art 80,0000 square foot manufacturing facility
https://www.youtube.com/